
    
      The objective of the study is to compare the effect of adding 2 oral hepatitis C virus (HCV)
      protease inhibitors, telaprevir versus boceprevir, as part of current standard treatment
      regimen with (pegylated-interferon-alpha + ribavirin) for HCV Genotype-1 infection. Data will
      be obtained from medical records of consenting patients.
    
  